论文部分内容阅读
我们在对钍的促排药物研究中,发现703-13对~(234)Th的促排具有一定的效果,但该药的刺激性较大,故未能过渡到临床使用。为此,在703-13药物的基础上进行改进,以图达到降低毒性提高疗效。703-13的结构是苯羟基磺酸羧氨酸类络合剂,在703-26的结构中包含有二个苯羟基磺酸,动物实验中观察到毒性较低,促排效果较703-13稍好。本文主要介绍703-26的药理研究和正常人使用后的毒性反应观察。
In our study on the promotion of Thorium, we found that 703-13 had some effect on the promotion of ~ (234) Th, but the drug was more irritating and therefore could not be switched to clinical use. To this end, 703-13 drugs based on the improvement in order to achieve reduced toxicity and improve efficacy. The structure of 703-13 is a phenyloxysulfonic acid carboxylate complexing agent, which contains two phenylhydroxy sulfonic acids in the structure of 703-26. In animal experiments, it was observed that the toxicity was lower and the promoting effect was 703-13 A little better. This article describes the 703-26 pharmacological studies and normal use of toxic reactions observed.